Georgiy Rubenovich Khachatryan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Georgiy Rubenovich Khachatryan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Vitaliy Vladimirovich Omelyanovskiy
Center for Healthcare Quality Assessment and Control; Russian Medical Academy of Continuing Professional Education
6 shared publications - Tatiana Pavlovna Bezdenezhnykh
General Practice, Royal College of Surgeons in Ireland, Dublin, Leinster
3 shared publications - Valeriya Aleksandrovna Lemeshko
Moscow Institute of Physics and Technology
2 shared publications - D. V. Fedyaev
Center for Healthcare Quality Assessment and Control; Russian Medical Academy of Continuing Professional Education; Financial Research Institute
1 shared publication - E. S. Saibel’
Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation
1 shared publication - Elena A. Maksimkina
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication
Latest Publications
- Open Access
- 29 April 2021
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 14 (1) , 5-15
Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy
Objective: the development and approbation of the method for comparative analysis of the lists of medicines in different countries and systems of healthcare.Material and methods. Based on the open-access data on the lists of medicines published on official websites of the authorized regulators, the authors selected the national lists of medicines of Russia, England, and Italy for the development and approbation of the method. It was proposed to use three parameters: the absolute number of medicines by international nonproprietary name (INN); the structure of the lists based on anatomical therapeutic chemical (ATC) classification; and the coverage of the indications based on the International Classification of Diseases, 10th edition (ICD-10). The results of the analysis provided grounds for the review of the approaches to the formation of the lists of medicines required for medical help in Russia, England, and Italy and reimbursed from the state budget.Results. The number of medicines by INN in the national lists of England and Italy exceeds the total number of drugs included in the list of vital essential and desirable (VED) in Russia. All the analyzed lists were characterized by an uneven distribution of medicines within the lists by the ATC groups. The lists of medicines in England and Italy significantly exceed the list of VED by the number of the included medicines by all ATC groups excluding groups J and H in comparison with Italy, and groups J and V in comparison with England. At the same time, the list of VED significantly exceeds the list in England by the number of covered indications from the ATC L group. During the approbation, the method showed to be effective and can be used for further comparative studies of the national lists of medicines.Conclusion. Non-uniform lists of medicines by ATC-codes show that each country has priority areas in their healthcare systems. The list of VED can be shorter by the absolute number of the included medicines in England and Italy but it can exceed them by the coverage of indications due to peculiarities of the procedure of the list formation (reimbursement of medicines by all the registered indications). The results of the study with the proposed method can serve for the optimization of the VED list and the analysis of therapeutic areas that are undercovered.
- 29 April 2021
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 14 (1) , 5-15
Open AccessDevelopment of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy
Objective: the development and approbation of the method for comparative analysis of the lists of medicines in different countries and systems of healthcare.Material and methods. Based on the open-access data on the lists of medicines published on official websites of the authorized regulators, the authors selected the national lists of medicines of Russia, England, and Italy for the development and approbation of the method. It was proposed to use three parameters: the absolute number of medicines by international nonproprietary name (INN); the structure of the lists based on anatomical therapeutic chemical (ATC) classification; and the coverage of the indications based on the International Classification of Diseases, 10th edition (ICD-10). The results of the analysis provided grounds for the review of the approaches to the formation of the lists of medicines required for medical help in Russia, England, and Italy and reimbursed from the state budget.Results. The number of medicines by INN in the national lists of England and Italy exceeds the total number of drugs included in the list of vital essential and desirable (VED) in Russia. All the analyzed lists were characterized by an uneven distribution of medicines within the lists by the ATC groups. The lists of medicines in England and Italy significantly exceed the list of VED by the number of the included medicines by all ATC groups excluding groups J and H in comparison with Italy, and groups J and V in comparison with England. At the same time, the list of VED significantly exceeds the list in England by the number of covered indications from the ATC L group. During the approbation, the method showed to be effective and can be used for further comparative studies of the national lists of medicines.Conclusion. Non-uniform lists of medicines by ATC-codes show that each country has priority areas in their healthcare systems. The list of VED can be shorter by the absolute number of the included medicines in England and Italy but it can exceed them by the coverage of indications due to peculiarities of the procedure of the list formation (reimbursement of medicines by all the registered indications). The results of the study with the proposed method can serve for the optimization of the VED list and the analysis of therapeutic areas that are undercovered.
- 1 January 2021
- Published by Russian Vrach, Publishing House Ltd. in Farmaciya (Pharmacy)
- Vol. 70 (1) , 40-45
Determination of incremental cost-effectiveness ratios of antitumor drugs
Введение. В настоящее время актуальным вопросом совершенствования процедуры комплексной оценки лекарственных препаратов (ЛП) при принятии решений об их включении в перечни ЛП для медицинского применения является определение и установление референтного значения инкрементального показателя «затраты/эффективность» (англ. Incremental Cost-Effectiveness Ratio, ICER). В соответствии с требованиями Постановления Правительства РФ №871 в случае, если предлагаемый ЛП характеризуется большей эффективностью и большей стоимостью, чем препарат сравнения, результаты клинико-экономического исследования необходимо представлять в виде соотношений «затраты/эффективность» для предлагаемого ЛП и препарата сравнения, а также показателя ICER. Однако необходимо определить стандартное значение,с которым бы в дальнейшем сравнивались значения ICER ЛП, предлагаемых к включению в данные перечни. Одним из возможных подходов к определению референтного значения ICER является анализ ранее принятых решений. Цель исследования: расчет и анализ значений ICER для противоопухолевых препаратов, предложенных к включению в перечень жизненно необходимых и важнейших лекарственных препаратов (ЖНВЛП) на 2018 г. Материал и методы. Был проведен анализ значений ICER противоопухолевых препаратов (АТХ-группа L01), уже включенных в перечень ЖНВЛП (2018), а также противоопухолевых препаратов, не одобренных к включению в данный перечень. Результаты. Медиана значений ICER противоопухолевых ЛП, включенных в перечень ЖНВЛП (2018), за один QALY для РФ составляет 7 494 944,00 руб. Значение ICER за один QALY для противоопухолевых ЛП, не включенных в перечень ЖНВЛП (2018), варьирует от 2 414 634,15 до 12 164 322,73 руб. Заключение. Проведенный анализ выявил значительный разброс показателя ICER ЛП, включенных в перечень ЖНВЛП (2018). Также были выявлены случаи, когда значения ICER препаратов, включенных в ЖНВЛП превышает ICER препаратов, не одобренных для включения в данный перечень. Для более точного определения референтого значения ICER для РФ необходимо проведение дальнейших исследований по расчету значений ICER для противоопухолевых и других препаратов, ранее включенных в перечень...
- 1 January 2021
- Published by Russian Vrach, Publishing House Ltd. in Farmaciya (Pharmacy)
- Vol. 70 (1) , 40-45
Determination of incremental cost-effectiveness ratios of antitumor drugs
Введение. В настоящее время актуальным вопросом совершенствования процедуры комплексной оценки лекарственных препаратов (ЛП) при принятии решений об их включении в перечни ЛП для медицинского применения является определение и установление референтного значения инкрементального показателя «затраты/эффективность» (англ. Incremental Cost-Effectiveness Ratio, ICER). В соответствии с требованиями Постановления Правительства РФ №871 в случае, если предлагаемый ЛП характеризуется большей эффективностью и большей стоимостью, чем препарат сравнения, результаты клинико-экономического исследования необходимо представлять в виде соотношений «затраты/эффективность» для предлагаемого ЛП и препарата сравнения, а также показателя ICER. Однако необходимо определить стандартное значение,с которым бы в дальнейшем сравнивались значения ICER ЛП, предлагаемых к включению в данные перечни. Одним из возможных подходов к определению референтного значения ICER является анализ ранее принятых решений. Цель исследования: расчет и анализ значений ICER для противоопухолевых препаратов, предложенных к включению в перечень жизненно необходимых и важнейших лекарственных препаратов (ЖНВЛП) на 2018 г. Материал и методы. Был проведен анализ значений ICER противоопухолевых препаратов (АТХ-группа L01), уже включенных в перечень ЖНВЛП (2018), а также противоопухолевых препаратов, не одобренных к включению в данный перечень. Результаты. Медиана значений ICER противоопухолевых ЛП, включенных в перечень ЖНВЛП (2018), за один QALY для РФ составляет 7 494 944,00 руб. Значение ICER за один QALY для противоопухолевых ЛП, не включенных в перечень ЖНВЛП (2018), варьирует от 2 414 634,15 до 12 164 322,73 руб. Заключение. Проведенный анализ выявил значительный разброс показателя ICER ЛП, включенных в перечень ЖНВЛП (2018). Также были выявлены случаи, когда значения ICER препаратов, включенных в ЖНВЛП превышает ICER препаратов, не одобренных для включения в данный перечень. Для более точного определения референтого значения ICER для РФ необходимо проведение дальнейших исследований по расчету значений ICER для противоопухолевых и других препаратов, ранее включенных в перечень...
- Open Access
- 9 August 2020
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 13 (2) , 113-123
Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871
Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871
- 9 August 2020
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 13 (2) , 113-123
Open AccessImprovements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871
Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871
- Open Access
- 24 April 2020
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 13 (1) , 71-83
Drug provision and health technology assessment in France
The article presents the description of structural, organizational and methodological issues of health technology assessment (HTA) of French drugs as well as the state-reimbursable list of drugs. The HTA is conducted by an independent public body – French National Authority for Health (HAS). HAS evaluates medical products, procedures, services and technologies from a medical and economic points of view to make cost recovery decisions. HAS consists of two committees providing HTA: Transparency Committee and the Economic and Public Health Assessment Committee. Thus, the French HTA consists of two separate components within the same agency. The result of HAS evaluation of a drug is a conclusion on the level of clinical value and clinical added value, as well as the methodological quality of the studies and the size of the target patient population. Based on the evaluation results, HAS gives recommendations for the National Union of Health Insurance Funds, the Economic Committee for Healthcare Products and Ministry of Health and publishes its opinion on the HAS website. HAS decisions are of a recommendatory nature – the final decision whether to include the drug in reimbursement lists are made by the Ministry of Health and published in the Official Journal of French republic.
- 24 April 2020
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 13 (1) , 71-83
Open AccessDrug provision and health technology assessment in France
The article presents the description of structural, organizational and methodological issues of health technology assessment (HTA) of French drugs as well as the state-reimbursable list of drugs. The HTA is conducted by an independent public body – French National Authority for Health (HAS). HAS evaluates medical products, procedures, services and technologies from a medical and economic points of view to make cost recovery decisions. HAS consists of two committees providing HTA: Transparency Committee and the Economic and Public Health Assessment Committee. Thus, the French HTA consists of two separate components within the same agency. The result of HAS evaluation of a drug is a conclusion on the level of clinical value and clinical added value, as well as the methodological quality of the studies and the size of the target patient population. Based on the evaluation results, HAS gives recommendations for the National Union of Health Insurance Funds, the Economic Committee for Healthcare Products and Ministry of Health and publishes its opinion on the HAS website. HAS decisions are of a recommendatory nature – the final decision whether to include the drug in reimbursement lists are made by the Ministry of Health and published in the Official Journal of French republic.
- Open Access
- 18 February 2020
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 12 (4) , 333-341
The health technology assessment system in Australia
In Australia, the federal government is in charge of providing the health care to patients. The government agencies determine the list of reimbursable pharmaceuticals and medical services and also define the preferential categories of the population. The states and territories may have their own health care programs in addition to the federal ones. The Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for the health technology assessment (HTA) and decides which technology is eligible for reimbursement by the federal budget. The drug evaluation process includes five stages: a review of general information about the product, assessment of its clinical efficacy, cost-effectiveness analysis, assessment of financial implications of including the drug in the reimbursement list, and consideration of any other factors that may influence the committee decision. In addition to the full reimbursement of pharmaceuticals, the committee may decide to provide funding based on a managed entry agreement.
- 18 February 2020
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 12 (4) , 333-341
Open AccessThe health technology assessment system in Australia
In Australia, the federal government is in charge of providing the health care to patients. The government agencies determine the list of reimbursable pharmaceuticals and medical services and also define the preferential categories of the population. The states and territories may have their own health care programs in addition to the federal ones. The Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for the health technology assessment (HTA) and decides which technology is eligible for reimbursement by the federal budget. The drug evaluation process includes five stages: a review of general information about the product, assessment of its clinical efficacy, cost-effectiveness analysis, assessment of financial implications of including the drug in the reimbursement list, and consideration of any other factors that may influence the committee decision. In addition to the full reimbursement of pharmaceuticals, the committee may decide to provide funding based on a managed entry agreement.
- Open Access
- 18 July 2019
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 12 (2)
Organizational structure and funding of health technology assessment agencies around the world
- 18 July 2019
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 12 (2)
Open AccessOrganizational structure and funding of health technology assessment agencies around the world
- Open Access
- 18 July 2019
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 12 (2)
Health technology assessment and reimbursement of pharmaceuticals in Italy
- 18 July 2019
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 12 (2)
Open AccessHealth technology assessment and reimbursement of pharmaceuticals in Italy
- Open Access
- 23 May 2019
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 12 (1) , 14-26
Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan
Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan
- 23 May 2019
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 12 (1) , 14-26
Open AccessEconomic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan
Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan